*ST东易10月9日公告，股票连续三个交易日收盘价格涨幅偏离值累计超过12%，属于股票交易异常波动 情形。鉴于公司2024年度末经审计的归母净资产为负值，根据相关规定，公司股票交易已被实施"退市 风险警示"；同时,鉴于公司连续三年实现的扣除非经常性损益后归属于母公司股东的净利润为负，大华 会计师事务所（特殊普通合伙）对公司2024 年度财务报表出具了带持续经营重大不确定性段落的无保 留意见审计报告，公司股票交易已被实施"其他风险警示"。2024年10月,公司收到北京市第一中级人民 法院送达的《决定书》，北京一中院决定对公司启动预重整。截至目前，公司尚未收到法院受理公司重 整申请的文书。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 4、经核实，公司、控股股东及实际控制人不存在应披露而未披露的重大事项。 5、经核实，股票异常波动期间，公司控股股东、实际控制人不存在买卖公司股票的情形。 三、是否存在应披露而未披露信息的说明 公司董事会确认，公司目前没有任何根据深圳证券交易所《股票上市规则》等有关规定应予披露而未披 露的事项；董事会也未获悉本公司有根据深圳证券交易所《股票上市规则》等有关规定应予披露而未披 露的、对股票交易价格产生较大影响的信息；公司前期披露的信息不存在需要更正、补充之处。 深圳瑞和建筑装饰股份有限公司（以下简称"公司"）股票（证券名称：ST瑞和；证券代码：002620） 于2025年9月24日、9月25日、9月26日连续三个交易日收盘价格涨幅偏离值累计超过12%，根据《深圳 证券交易所交易规则》的有关规定，属于股票交易异常波动情形。 二、公司关注并核实情况的说明 针对公司股票交易异常波动，截止本公告披露日，公司对相关事项进行了核实，现将有关情况说明如 下： ...

Group 1 - The company held its 15th meeting of the 9th Board of Directors on September 26, 2025, with all 9 directors present, and the meeting was chaired by Chairman Chen Zhijian [2][3] - The board approved a proposal regarding the acceptance of a gratuitous guarantee from related parties for its subsidiary, Cangzhou Lingang Yanuo Chemical Co., Ltd., with a voting result of 7 in favor and 0 against [2][8] - The guarantee provided by the controlling shareholder, Guangzhou Wanshun Technology Co., Ltd., and related party Guangdong Wanjia Tong Holdings Co., Ltd., amounts to a maximum of RMB 49.47 million [7][13] Group 2 - The guarantee is gratuitous, meaning no fees will be charged, and no counter-guarantee is required [7][21] - The guarantee will terminate if the company successfully completes its restructuring and meets specific conditions, including maintaining an asset-liability ratio below 60% [7][20] - The independent directors unanimously agreed that the guarantee is beneficial for the subsidiary's stable development and does not harm the interests of the company or its minority shareholders [25][23] Group 3 - The company received a decision from the Beijing Arbitration Commission to withdraw a case involving disputes with its shareholders, which will not affect the company's control or financial performance [28][29] - The arbitration case was initiated due to disagreements over a cooperation agreement and a voting rights entrustment agreement [32][34] - The withdrawal of the arbitration request was made by the applicants, and the arbitration fee was partially refunded [34][35]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002168 证券简称：*ST惠程 公告编号：2025－079 2025年第四次临时股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，不存在虚假记载、误导性陈述或者重大遗 漏。 特别提示 1.本次股东会未出现否决提案的情形； 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开情况 1.召集人：公司董事会 2.表决方式：采取现场表决与网络投票相结合的表决方式 3.现场会议召开时间为：2025年9月15日（星期一）14:30 4.会议召开地点：重庆市璧山区璧泉街道双星大道50号1幢8楼会议室 5.主持人：公司董事长艾远鹏先生 6.本次会议的召集、召开符合《中华人民共和国公司法》《上市公司股东会规则》《深圳证券交易所股 票上市规则》及《公司章程》等有关规定。 二、会议的出席情况 出席本次会议的股东及股东代理人138人，代表公司股份108,127,153股，占公司总股份784,163,368股的 13.7889%。出席本次股东会的中小股东共137人，代表公司股份12,823,242股，占公司总股份的 1.6353%。 本次股东 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 一、股票交易异常波动具体情况 中基健康产业股份有限公司（以下简称"公司"或"中基健康"）股票（证券简称：*ST中基，证券代码：000972）， 于2025年9月11日、2025年9月12日、2025年9月15日连续三个交易日收盘价格跌幅偏离值累计偏离-15.42%。根据 《深圳证券交易所交易规则》的相关规定，属于股票交易异常波动。 二、公司关注并核实的相关情况 针对公司股票异常波动情况，按照相关规定的要求，公司对有关事项进行了核查，现就核实情况说明如下： 1、经公司自查，近期公司生产经营情况正常，内外部经营环境未发生重大变化； 2、前期披露的信息不存在需要更正、补充之处 3、2025年7月28日，中基健康及公司下属全资子公司新疆中基红色番茄产业有限公司（以下简称"红色番茄"）分 别收到新疆生产建设兵团第六师中级人民法院（以下简称"六师中院"或"法院"）送达的《预重整通知书》 [（2025）兵06破申（预）1号、（2025）兵06破申（预）2号]。六师中院通知启动对公 ...

Core Viewpoint - ST Dongshi (603377) has experienced a price increase of 4.78% this week, closing at 3.73 yuan, with a total market capitalization of 2.738 billion yuan as of September 12, 2025 [1] Company Announcements - Dongshi Driving School received a court decision on July 10, 2025, to initiate pre-restructuring, with uncertainty regarding formal restructuring proceedings [2] - The company is actively seeking restructuring investors and signed a restructuring investment agreement on August 19, 2025 [2] - The company is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations, with potential delisting risks for its stock and convertible bonds [2][5] Legal Issues - A subsidiary of Dongshi Driving School is involved in a lawsuit initiated by Shanghai Pudong Development Bank, with a total claim amounting to approximately 201.5 million yuan [3] - The company has reported five additional lawsuits, with a total claim amount of approximately 203.5 million yuan, representing 21.96% of the latest audited net assets [3] Shareholder Changes - The controlling shareholder, Dongshi Investment, auctioned off 56,491,600 shares, which were successfully acquired by Anhui Rongzhi Management Consulting Partnership for approximately 169 million yuan [4] - If the transfer is completed, the combined shareholding of Dongshi Investment and its concerted action party will decrease to 6.98% [4]

Core Viewpoint - The board members of *ST Asia Pacific expressed concerns over the company's financial reporting and governance issues, highlighting a significant internal conflict during a critical restructuring phase [2][3]. Group 1: Board Disagreement - On August 26, 2025, board members Jia Mingqi and Zhao Yong voted against the approval of the 2025 semi-annual report, citing a lack of understanding of the company's operational and financial conditions [2]. - The company responded by stating that it had not received any prior inquiries or requests for information from the dissenting board members [2]. Group 2: Governance and Control Issues - Jia Mingqi's position as a representative of shareholders with significant stakes (16.94%) adds weight to the dissent, as these shareholders are involved in a control struggle with the restructuring applicant, Guangzhou Wanshun Technology Co., Ltd. [2]. - The ongoing control dispute is reflected in the board's disagreement, indicating deeper governance issues within the company [2]. Group 3: Restructuring Challenges - The restructuring process is under threat due to the board's dissent, which could attract regulatory scrutiny and delay the ongoing restructuring efforts [3]. - As of September 8, 2025, Beijing Xingjian Changkong Technology Co., Ltd. was selected as the restructuring investor, but formal agreements had not yet been signed, raising concerns about the feasibility of the restructuring plan [4]. Group 4: Financial Crisis and Risks - The company faces a financial crisis, with a net asset value of -64.81 million yuan as of 2024, triggering delisting risk [4]. - The company reported a net loss of 23.72 million yuan in the first half of 2025, a 67.13% decline year-on-year, indicating worsening financial health [4]. - The restructuring process is complicated by legal uncertainties and potential disputes over control, which could jeopardize the company's survival [4].

Group 1 - The core point of the article is that *ST Zhongji has made significant progress in its pre-restructuring efforts, with the selection of Xinjiang Xinye State-owned Assets Management Group as the industrial investor and seven financial investors [1] - The agreement states that Xinjiang Xinye will acquire 276 million shares at a price of 1.81 yuan per share, totaling approximately 500 million yuan, while financial investors will acquire 240 million shares at 2.52 yuan per share, totaling 617 million yuan [1] - Following the restructuring, the total share capital of the company will increase from 770 million shares to 1.619 billion shares, with Xinjiang Xinye potentially becoming the controlling shareholder [1] Group 2 - The restructuring is expected to improve the financial structure and alleviate the debt crisis, while also introducing new capital to restore ongoing operational capabilities [2] - However, the company still faces delisting risks if the audited net profit for 2024 is negative, and if the operating revenue is below 300 million yuan, with negative net assets [2] - In the secondary market, *ST Zhongji recorded nine trading limits within 18 trading days, with a cumulative increase of 45.63% [2] Group 3 - As of June 2025, the company's total operating revenue was 245 million yuan, a slight decrease of 0.08% year-on-year, and it reported a net loss of 74.7031 million yuan [3]

Core Viewpoint - The article highlights the importance of bankruptcy restructuring as a means for companies to recover from financial distress, emphasizing that bankruptcy can provide a second chance rather than being an end point for businesses [1][2]. Group 1: Bankruptcy Restructuring - The case of a Shanghai-based company, which faced severe financial difficulties and was on the verge of judicial auction, illustrates how bankruptcy restructuring can revitalize a business [1][2]. - The Shanghai Bankruptcy Court has seen a significant increase in cases, with 4,911 cases in 2023 and an expected 5,050 in 2024, indicating a high demand for bankruptcy services [1]. - The company underwent an out-of-court restructuring process, which allowed it to negotiate with creditors and stabilize its operations, ultimately leading to the approval of its restructuring plan by the court [3][4]. Group 2: Market-Oriented Solutions - The establishment of the North Bund Enterprise Out-of-Court Restructuring Center in Hongkou District represents a proactive approach to facilitate market-oriented restructuring solutions [3]. - The restructuring process involved the company negotiating with over two-thirds of its creditors to sign restructuring agreements, resulting in a debt restructuring of nearly 4 billion yuan [3]. - The flexibility and confidentiality of out-of-court restructuring allow companies to navigate financial crises without public scrutiny, which can be beneficial for maintaining business operations [2]. Group 3: Judicial Support and Pre-Reorganization - The Shanghai courts have implemented a "pre-reorganization" system to assist companies in distress before they enter formal bankruptcy proceedings, enhancing the chances of recovery [5][6]. - The case of Shanghai Jubao Real Estate Development Co., which faced a funding crisis, demonstrates how pre-reorganization can lead to successful asset recovery and debt repayment [6]. - The court's involvement in guiding the restructuring process has proven effective in ensuring that creditors are repaid and that companies can resume operations [6]. Group 4: Liquidation and Asset Management - Not all companies can be saved; some must undergo liquidation to ensure an orderly exit from the market, which can prevent further disputes and protect creditor interests [8][9]. - The case of Shanghai Shangshu Yonghui Fresh Food Co. illustrates the importance of asset management during liquidation, where the court facilitated the sale of assets to clear debts amounting to over 570 million yuan [9]. - The bankruptcy process serves not only to distribute assets but also to inject capital back into the economy, highlighting its role in resource reallocation [9].

Core Viewpoint - *ST Huicheng has selected Zhi'en Biotechnology as the restructuring investor during its pre-restructuring phase, but no formal agreement has been signed yet, leaving future collaboration uncertain [1][2] Group 1: Company Developments - *ST Huicheng has experienced a stock price increase of 15.83% over three consecutive trading days, followed by a decline of 4.95% on the latest trading day, closing at 4.80 yuan [1] - The company has initiated the recruitment of restructuring investors since August 9, with three potential investors meeting the requirements and submitting their materials [1] - Zhi'en Biotechnology was selected as the restructuring investor based on a comprehensive evaluation of submitted restructuring investment proposals [1][2] Group 2: Zhi'en Biotechnology Overview - Zhi'en Biotechnology, established in April 2001, focuses on building a drug lifecycle management service system and holds various qualifications, including being a national high-tech enterprise [2] - The company has over 50 products, including key medications such as orlistat capsules for weight loss and donepezil hydrochloride tablets for Alzheimer's disease [2][3] - Zhi'en Biotechnology is the largest global supplier of orlistat, having achieved full synthetic industrial production of the active pharmaceutical ingredient [3] Group 3: Previous Collaborations - Prior to the restructuring investment selection, *ST Huicheng and Zhi'en Biotechnology had collaborated, with *ST Huicheng acquiring a 51% stake in Chongqing Rui'en Pharmaceutical for 47 million yuan [4] - The biopharmaceutical business, including Rui'en Pharmaceutical, has become a significant revenue contributor for *ST Huicheng, accounting for 57.41% of its revenue in the first half of the year [4] - Rui'en Pharmaceutical reported a revenue of 122 million yuan and a net profit of 23.44 million yuan in the first half of the year [4]